Syndax Pharmaceuticals
Syndax Pharmaceuticals Inc is an American clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative targeted therapies for the treatment of cancer and autoimmune diseases, prominently featuring revolutionary oncology products such as revumenant (a menin inhibitor) and SNDX-6352 (axatilimab) for chronic graft-versus-host disease. The company conducts advanced clinical trials evaluating novel cancer therapeutics intended to improve patient survival and treatment response. Its core business operations encompass biopharmaceutical oncology research, clinical trial execution, drug formulation development, and commercial pharmaceutical strategy. As a commercial-stage biotechnology enterprise, the company generates revenue through pharmaceutical product sales and commercial milestone agreements. Syndax Pharmaceuticals holds a pioneering market position in targeted oncology and menin inhibition. The company is headquartered in Waltham, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market.
7 of the funds FundTelligence covers report a position in Syndax Pharmaceuticals.
- Legal name
- Syndax Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 7
Funds holding Syndax Pharmaceuticals
- DNB Bioteknologi — DNB · 1.36 % (full portfolio disclosed, September 2026)
- BNP Health Care Innovators — BNP Paribas · 0.99 % (full portfolio disclosed, June 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.97 % (full portfolio disclosed, September 2026)
- BNP US Small Cap — BNP Paribas · 0.86 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.08 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)